Water-injecting Endoscopic Submucosal Dissection for Early Gastric Cancer: a Retrospective Cohort Study
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, Shanghai East Hospital
- Shanghai East Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- age ≥ 18 years;
- histologically proven early gastric adenocarcinoma;
- meeting the absolute or expanded indication for ESD according to the Japanese gastric cancer treatment guidelines 2021 ;
- Eastern Cooperative Oncology Group performance status ≤ 2;
- adequate hematological function (hemoglobin ≥ 9 g/dL, platelets ≥ 50 000/mm3,international normalized ratio<1.5);
- sufficient renal function (serum creatinine ≤ 2.0 mg/dL); and (7) adequate hepatic function (serum aspartate aminotransferase ≤ 100 IU/L, serum alanine aminotransferase ≤ 100 IU/L).
Exclusion Criteria:
- pregnancy or breastfeeding;
- difficulty obtaining consent due to psychiatric disorder;
- multiple lesions;
- history of gastrectomy or gastrointestinal reconstruction surgery.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Water-injecting ESD
A new ESD method using continuous low-pressure water injection at 1-2 atmosphere with a tip-injected electric knife while dissection simultaneous cutting, dissection, electrocoagulation, and hemostasis, which was so called as water-injecting ESD (W-ESD).
|
|
Conventional ESD
A traditional ESD model.
Submucosal injection is performed separately from circumferential cutting, dissection, electrocoagulation, and hemostasis.
During the submucosal dissection procedures, submucosal injection is performed with the tip of the knife first, followed by the above operations, rather than simultaneously.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total procedure time
Time Frame: Immediately after surgery
|
Average time to complete endoscopic resection
|
Immediately after surgery
|
|
Circumferential incision time
Time Frame: Immediately after surgery
|
Average time for APC labeling of the lesion margin during circumferential incision
|
Immediately after surgery
|
|
Dissection time
Time Frame: Immediately after surgery
|
Average time to complete endoscopic dissection
|
Immediately after surgery
|
|
Dissection speed
Time Frame: Immediately after surgery
|
Average speed of endoscopic dissection
|
Immediately after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Completeness of en bloc resection
Time Frame: Immediately after surgery
|
Number of patients with complete lesion resection / Total number of subjects
|
Immediately after surgery
|
|
Adverse event rate
Time Frame: Immediately after surgery and one month post-surgery
|
The proportion of adverse events occurring in subjects following surgery (though not necessarily causally related to treatment), encompassing perforation complications, myomere injuries, intraoperative blood loss, thermocoagulation forceps replacements, delayed bleeding, and delayed perforation.
|
Immediately after surgery and one month post-surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20250612IIT0068
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Early Gastric Cancer
-
NCT01688687CompletedEarly Gastric Cancer | Gastric Dysplasia
-
NCT01832246UnknownEarly Gastric Cancer | Gastric Tumor
-
NCT04665687RecruitingEarly Gastric Cancer | Gastric Adenoma
-
NCT07405931RecruitingEarly Gastric Cancer | Advanced Breast Cancer | Early Breast Cancer | Advanced Gastric Cancer | Advanced Lung Cancer | Early Lung Cancer | Early Colon Cancer | Advanced Colon Cancer
-
NCT02504164CompletedEarly Gastric Cancer | Gastric Adenoma
-
NCT01806753CompletedEarly Gastric Cancer | Gastric Adenoma
-
NCT06788548Recruiting
-
NCT06152783Not yet recruiting
-
NCT04411589Unknown
-
NCT03136354Completed